Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

ClinicalTrials.gov ID: NCT07787169

Public ClinicalTrials.gov record NCT07787169. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Aug 27, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 or A1D-MC-AT02 (upcoming).

Study identification

NCT ID
NCT07787169
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
179 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028
Last update posted
Aug 25, 2026

2026 – 2028

United States locations

U.S. sites
10
U.S. states
4
U.S. cities
10
Facility City State ZIP Site status
Irvine Clinical Research Irvine California 92614
Fortrea Clinical Research Unit Daytona Beach Florida 32117
K2 Medical Research - The Villages Lady Lake Florida 32159
K2 Medical Research Maitland Florida 32751
Charter Research Orlando Florida 32803
Progressive Medical Research Port Orange Florida 32127
K2 Medical Research - Tampa Tampa Florida 33634
Charter Research The Villages Florida 32162-2698
Accel Research Sites - NeuroStudies Clinical Research Unit Decatur Georgia 30030
QUEST Research Institute Farmington Hills Michigan 48334

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Alzheimer Disease trials

Other public records listing Alzheimer Disease. Sorted by last update posted; newest first. Not a recommendation.

All Alzheimer Disease trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07787169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2026 · Synced Aug 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07787169 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →